LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/08/2026
Voltar para busca
Dado oficial do USPTO
DUOHEXABODY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
DUOHEXABODY
ST13
US500000079253337Classe
1, 5, 42, 45
Pedido
79253337
Registro
5993053
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
04/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 45
Data de depósito
15/11/2018
Data de registro
25/02/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/06/2026
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
Utrecht, NL
Examinador
CAPSHAW, DANIEL
Localização atual
Historical data usage
Titulares e representantes
Titulares
Genmab Holding B.V.
Genmab Holding B.V.
Representantes
Max Vern AMSTER, ROTHSTEIN & EBENSTEIN LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemicalbiologicalbiotechnological preparationsantibodiesbi- and multispecific antibodies as well as antibody fragmentsincluding monovalent antibodiesderivatives or conjugates of any of thesefor in vitro and in vivo scientific and industrial research and development with regard to diseases; Active chemical ingredients for use in the manufacture of pharmaceuticals
Classe 5
Pharmaceutical and veterinary preparationspharmaceutical preparations based on antibodiesbi- and multispecific antibodies as well as antibody fragmentsincluding monovalent antibodiesderivatives or conjugates of any of these for use with regard to the treatment of cancerinfectiousimmuneautoimmuneinflammatoryneurodegenerative and cardiovascular diseases
Classe 42
Medicalscientific and biological researchespecially research into antibodies and bi- and multispecific antibodies or fragmentsincluding monovalent antibodiesderivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragmentsincluding monovalent antibodiesderivatives or conjugates of any of these; chemical analysis; computer programmingprogramming of computers for the collection and processing of medical data in medical scientific researchdevelopment and therapyincluding scientific researchdevelopment and therapy with antibodies and bi- and multispecific antibodies or fragmentsincluding monovalent antibodiesderivatives or conjugates of any of these
Classe 45
Legal services in the field of patent exploitationpatent consultationpatent licensingproviding information about patent rights; licensing of intellectual property in the field of medicine
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
16/06/2026
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
16/06/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/06/2026
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
05/03/2026
ES71
TEAS SECTION 71 RECEIVED
24/02/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/04/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
25/02/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/06/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/06/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/06/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/06/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/06/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/06/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/07/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/06/2020
FIMP
FINAL DISPOSITION PROCESSED
22/06/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/05/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
25/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/12/2019
PUBO
PUBLISHED FOR OPPOSITION
10/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/11/2019
ALIE
ASSIGNED TO LIE
05/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/10/2019
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
31/10/2019
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
19/09/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
13/09/2019
GNSL
LETTER OF SUSPENSION E-MAILED
13/09/2019
CNSL
SUSPENSION LETTER WRITTEN
13/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/09/2019
RFNT
REFUSAL PROCESSED BY IB
06/04/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/03/2019
RFRR
REFUSAL PROCESSED BY MPU
20/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
12/03/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/03/2019
CNRT
NON-FINAL ACTION WRITTEN
07/03/2019
DOCK
ASSIGNED TO EXAMINER
06/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/03/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/02/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DUOHEXABODY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.